Notably, mutations in the FMS‐like tyrosine kinase 3 (FLT3) gene observed in 25%–35% of AML patients have been definitively linked to leukemia progression, increased cell proliferation, and unfavorable prognosis.10, 11, 12. Here, FLT3 is linked to acute myeloid leukemia.